Growth after hematopoietic stem cell transplantation in children with acute myeloid leukemia by unknown
POSTER PRESENTATION Open Access
Growth after hematopoietic stem cell
transplantation in children with
acute myeloid leukemia
Seung Joon Chung*, Jieun Lee, Min Jae Kang, Choong Ho Shin, Sei Won Yang
From 7th APPES Biennial Scientific Meeting
Nusa Dua, Bali. 14-17 November 2012
Previous studies have shown that hematopoietic stem cell
transplantation (HSCT) may result in growth impairment.
Disease type, differences in treatment before HSCT and
treatment duration before HSCT can affect growth after
HSCT and act as confounding variables. By contrast, acute
myeloid leukemia (AML) patients receive HSCT during
their first remission and are not treated by steroids during
their relatively short period of induction therapy time. The
purpose of this study was to evaluate 5 years growth after
HSCT and to find factors influencing final adult height
(FAH) in childhood AML patients.
Among 97 AML patients whom received HSCT in Seoul
National University Hospital, we report 24 patients whose
puberty began at least 3 years after HSCT and 19 patients
who reached FAH without relapse. Medical records were
retrospectively reviewed. Summary measure analysis was
used to evaluate for 5 year growth after HSCT and to find
statistical differences between factors. Univariate and mul-
tivariate regression analysis was performed to find factors
influencing FAH.
Five years growth after HSCT: Patients received HSCT
at 4.2 years of age. Six patients received radiotherapy
(RT) and chronic GVHD (cGVHD) were in 4 patients.
History of RT and cGVHD significantly impaired the
first 5 years growth after HSCT. But cGVHD seems to
influence to only the first 2 years growth after HSCT.
Age at HSCT, gender and history of steroid use were
not significantly affected 5 years growth after HSCT.
Final adult height after HSCT: Patients received HSCT
at 10.1 years of age. Four patients received RT. In patients
reached FAH without relapse after HSCT, only history of
RT significantly reduced FAH. Age at HSCT, gender and
history of steroid use were not significantly affected FAH.
Growth impairment after HSCT in AML patients might
be occurred. But without RT history, growth impairment
seems to be temporary and improve by catch-up growth.
HSCT with conditioning regimen consists of only che-
motherapy thought to be not to significantly decrease
FAH. So the growth hormone treatment is seems to be
not needed in non-RT patients. But in patients who
received RT, catch-up growth will not be shown and even-
tually attain reduced FAH.
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